骨毒性病例报告 结合恩科拉费尼布,塞图西马布和WNT974在第一阶段试验中
Mark T J VAN Bussel1, Nathalie Bravenboer2,3, Huib VAN Essen3
1Department of Clinical Pharmacology, The Netherlands Cancer Institute, Amsterdam, the Netherlands m.v.bussel@nki.nl.
Anticancer research
|June 27, 2025
概括
两名患有晚期结直肠癌的患者经历了严重的骨毒性,包括骨折和脊椎崩,当他们接受BRAF,EGFR和猪类抑制剂的联合治疗时. 这突显了癌症治疗中双MAPK和WNT通路抑制的潜在骨风险.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 药理学 药理学是指药理学的学科.
背景情况:
- 大肠直肠癌 (CRC) 经常涉及WNT信号通路的改变.
- BRAFV600E突变发生在8-10%的KRAS-WT转移性CRC (mCRC) 患者中,这些患者从EGFR抗体中获得的益处有限.
- 通过鱼类抑制剂准WNT信号可能会增强BRAFV600E突变mCRC的治疗反应.
研究的目的:
- 报告在接受包括BRAF抑制剂,EGFR抗体和猪抑制剂在内的联合治疗的患者中观察到的严重骨毒性.
- 研究与mCRC中双MAPK和WNT通路抑制相关的潜在骨风险.
主要方法:
- 两名患有BRAFV600E突变,KRAS-WT mCRC和WNT通路变化的患者的病例报告.
- 治疗包括恩科拉费尼布 (BRAF抑制剂),塞图西马布 (EGFR抗体) 和WNT974 (猪类抑制剂).
- 评估包括临床评估,尸检,骨组织学和WNT通路组件的免疫组织化学.
主要成果:
- 患者1患有多重肋骨骨折和胸部脊椎崩,骨质疏松性骨变化.
- 患者2患有骨折,骨质疏松症和骨生物标志物发生变化,表明骨循环中断.
- 组织学揭示了患者1的薄皮层和椎骨结构不佳.
结论:
- 双重MAPK和WNT通路的抑制可以导致严重的骨毒性,包括骨折和骨质疏松性崩.
- 观察到高血症和改变的骨生物标志物,这表明骨代谢发生了显著的破坏.
- 这些发现强调了需要对接受这种组合治疗的患者骨健康保持警的需要.
关键词:
骨折 骨折 骨折 骨折 骨折 骨折 骨折这是CTX CTX CTX.在P1NP中,P1NP是P1NP抑制WNT的抑制 WNT的抑制这就是 cetuximab 的意思.这就是encorafenib.过高血症的情况.转移性结直肠癌 转移性结直肠癌猪类抑制剂的抑制剂更多相关视频
15:04Potentiation of Anticancer Antibody Efficacy by Antineoplastic Drugs: Detection of Antibody-drug Synergism Using the Combination Index Equation
Published on: January 19, 2019
12.3K
09:49Dual-phase Cone-beam Computed Tomography to See, Reach, and Treat Hepatocellular Carcinoma during Drug-eluting Beads Transarterial Chemo-embolization
Published on: December 2, 2013
10.4K
相关概念视频
02:56Treatment Resistant Cancers
3.4K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.4K
02:50Combination Therapies and Personalized Medicine
5.1K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.1K
02:49Cancer Therapies
8.0K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
8.0K